drugset / Trial / NCT00759551

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

NCT00759551

Phase 2 Completed 555 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of azilsartan, once daily (QD), in subjects with essential hypertension.

Timeline

Start
2004-08
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 2.5 mg Oral
Subject Azilsartan Unknown 5 mg Oral
Subject Azilsartan Unknown 10 mg Oral
Subject Azilsartan Unknown 20 mg Oral
Subject Azilsartan Unknown 40 mg Oral
Comparator Olmesartan Other / unclassified 20 mg Oral